Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:08:37 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:QURE - UNIQURE N.V. - https://www.uniqure.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
QURE - Q0.125.25·26.500.125.65+1.134.61,727.944,13815,29125.55  28.03  25.2071.50  7.7619:47:0807:0515 min RT 2¢

Recent Trades - Last 10 of 15291
Time ETExPriceChangeVolume
19:47:08Q24.9940.474100
19:44:20Q25.601.0867
19:26:38Q25.631.11200
19:17:21Q26.271.7529
19:04:58Q26.011.4930
19:02:52Q25.771.2510
19:02:52Q25.561.041
19:02:52Q25.551.0319
19:02:36Q25.821.3010
19:02:36Q25.591.071

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-06 07:05U:QURENews ReleaseuniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in alpha-Gal A Enzyme Activity in Patients with Fabry Disease
2026-01-17 11:48U:QURENews ReleaseNotice of QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
2026-01-09 07:05U:QURENews ReleaseuniQure Announces Type A Meeting Scheduled with FDA
2025-12-04 07:05U:QURENews ReleaseuniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
2025-11-10 07:05U:QURENews ReleaseuniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-06 07:05U:QURENews ReleaseuniQure to Announce Third Quarter 2025 Financial Results
2025-11-03 07:05U:QURENews ReleaseuniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
2025-09-29 16:05U:QURENews ReleaseuniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
2025-09-25 23:39U:QURENews ReleaseuniQure Announces Pricing of Upsized $300 Million Public Offering
2025-09-24 16:07U:QURENews ReleaseuniQure Announces $200 Million Proposed Public Offering
2025-09-24 07:10U:QURENews ReleaseuniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
2025-09-24 07:05U:QURENews ReleaseuniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease
2025-09-05 07:05U:QURENews ReleaseuniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in alpha-Gal A Enzyme Activity in Patients with Fabry Disease
2025-07-29 07:05U:QURENews ReleaseuniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
2025-07-22 07:05U:QURENews ReleaseuniQure to Announce Second Quarter 2025 Financial Results
2025-06-11 08:00U:QURENews ReleaseuniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer
2025-06-02 07:05U:QURENews ReleaseuniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
2025-05-29 07:05U:QURENews ReleaseuniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
2025-05-19 08:00U:QURENews ReleaseCorbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
2025-05-09 07:05U:QURENews ReleaseuniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress